NKGen Biotech, Inc. (NKGN)
- Previous Close
1.2400 - Open
1.2500 - Bid 1.1300 x 200
- Ask 1.1600 x 200
- Day's Range
1.1150 - 1.2500 - 52 Week Range
0.7800 - 6.7000 - Volume
159,612 - Avg. Volume
3,706,991 - Market Cap (intraday)
25.644M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-5.3800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
nkgenbiotech.comRecent News: NKGN
Performance Overview: NKGN
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKGN
Valuation Measures
Market Cap
27.89M
Enterprise Value
47.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.22k
Price/Book (mrq)
--
Enterprise Value/Revenue
964.78
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-113.32%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-82.95M
Diluted EPS (ttm)
-5.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
26k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
11.32M
Research Analysis: NKGN
Company Insights: NKGN
NKGN does not have Company Insights